Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2018 call → NOWe need to determine if management's forward account is substantially about counterparties' own growth/expansion, with the company already inside that growth, and early/large relative to company. Key parts: VIVITROL growth tied to state/federal policies, legislation, treatment centers. ARISTADA growth tied to hospital formularies, sales force expansion. 5461/3831 pipeline. 4230 clinical. Management speaks about counterparties? For VIVITROL, they mention states, legislation, comprehensive opioid recovery centers, state collaborative grants. But these are policy initiatives, not specific counterparties' own business ramps. They describe "we continue to collaborate with federal, state and local policymakers" - but that's not reporting on counterparties' own scaling. They mention "27 states have demonstrated more than 25% growth" - that's market data, not counterparties' own plans. They don't describe specific payers, providers, or programs that they supply and whose expansion drives their volume. For ARISTADA, they mention "addition of both ARISTADA and ARISTADA INITIO to formularies at more than 30 hospitals during the quarter" - that's a result of their selling effort, not counterparties' own trajectory. They also mention expanding sales force themselves. The question asks: does management narrate what its counterparties are themselves doing and scaling? For example, describing a partner's launch, a distributor's expansion, a payer's program build-out. Here, management talks about its own actions (sales force expansion, sampling, studies) and broad policy/market conditions. They don't describe specific counterparties' own business plans as the driver. The closest is maybe the federal legislation providing funding, but that's not a counterparty they supply. They are not reporting on a specific customer's ramp. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.